Aptamer Group Advances Optimer® Delivery Vehicles to Final Commercial Development with Genetic Medicines Customer

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced that a genetic medicines customer has selected to progress to the final commercial development phase for Optimer delivery vehicles.

Over the past ten months, Aptamer has successfully developed Optimer delivery vehicles and shipped Optimer test material to the customer during October 2024. The performance of these delivery vehicles has been validated by the customer, indicating that the Optimer delivery vehicles can specifically target the required cell type, with the potential to be used as part of a precision therapy, which would deliver downstream licensing revenue for Aptamer.

The same customer has also successfully demonstrated Optimer binding to the target cells from a panel of different animal species. This pan-species specificity is highly desirable to facilitate progression through preclinical development, where testing in multiple animal species is often used before testing in humans. Due to the targeting specificity, multiple species binding, and reproducibility of the results, the customer has committed to progressing to the final commercial development stage for the therapeutic delivery vehicle.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Aptamer Group

    More articles like this

    Aptamer Group

    Aptamer Group to host webinar and Q&A session for investors

    Aptamer Group plc (LON: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced that Dr Arron Tolley, Chief Executive Officer and Dr David Bunka, Chief Scientific Officer will be hosting a

    Aptamer Group

    Aptamer Group secures new contracts worth up to £471,000

    Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has provided an update on contracts signed since its financial year ended 30 June 2024. Aptamer has secured new contracts

    Aptamer Group

    Aptamer making significant progress commercially and technically

    Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced its full year results for the twelve months ended 30 June 2024. Highlights ·      New strategic approach launched in August

    Aptamer Group

    Aptamer Group appoints Tim Sykes as a Non-Executive Director

    Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced the appointment of Tim Sykes to its Board of Directors as a Non-Executive Director with immediate effect. Tim